A University of Texas System patent describes new allosteric modulators of 5-HT2A and/or 5-HT2C receptors potentially useful for the treatment of obesity, substance abuse and dependence, mood and seizure disorders.
Takeda Pharmaceutical Co. Ltd. has identified N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives acting as somatostatin SST4 receptor agonists and thus reported to be useful for the treatment of Alzheimer’s disease, depression, schizophrenia, autism, epilepsy, pain, bipolar and anxiety disorder.
Morphinan derivatives acting as κ-opioid receptor agonists have been discovered by Toray Industries Inc. They are reported to be useful for the treatment of pain, hepatobiliary and hematologic diseases, cardiovascular and respiratory disorders.
Research at the University of Florida has led to the identification of compounds acting as dual dopamine transporter (DAT) and sigma receptor (sigma nonopioid intracellular receptor 1 [σ1, SIGMAR1] and sigma intracellular receptor 2 [σ2, TMEM97]) antagonists reported to be useful for the treatment of methamphetamine dependence and cocaine dependency.
Epoxysqualene-lanosterol cyclase (lanosterol synthase, OSLC) inhibitors have been reported in a University of Texas System patent as potentially useful for the treatment of amyotrophic lateral sclerosis, glioblastoma, multiple sclerosis, neurodegeneration, Parkinson’s, Alzheimer’s and Huntington’s diseases.
Escient Pharmaceuticals Inc. has patented quinoline derivatives acting as Mas-related G protein-coupled receptor member X2 (MRGPRX2) antagonists and thus reported to be useful for the treatment of pain, psoriasis, inflammatory disorders, atopic dermatitis, eczema, pruritus, urticaria and autoimmune disease, among others.
Celero Systems Inc. reported details of a patent filing for gastric residency systems for its ingestible devices, in the form a plurality of retention arms with non-deployed and deployed states sized and configured to temporarily retain the ingestible devices in the stomach for periods of up to a week.
Mindrank AI Co. Ltd. has described macroheterocyclic compounds acting as ALK mutant and ROS1 inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Chemocentryx Inc. has divulged chemokine CXCR6 receptor antagonists reported to be useful for the treatment of cancer, autoimmune hepatitis, ischemia-reperfusion injury, myocardial ischemia, autoimmune disease and inflammatory disorders.
RSS
